πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 379 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 9029338

Lipid formulated compositions and methods for inhibiting expression of a gene from the ebo

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 12 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9012624

Compositions and methods for inhibiting expression of a gene from the JC virus

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9012498

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 21 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9006197

Compositions and methods for inhibiting expression of Eg5 and VEGF genes

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 14 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9000143

Compositions and methods for inhibiting expression of IKK-B gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Apr 07 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8993746

Nuclease resistant double-stranded ribonucleic acid

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 31 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8987377

Poly(amide) polymers for the delivery of oligonucleotides

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8987227

Hepatitis C dsRNA effector molecules, expression constructs, compositions, and methods of

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8962580

Chemical modifications of monomers and oligonucleotides with cycloaddition

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8957223

Ligand-conjugated monomers

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8889644

GNAQ targeted dsRNA compositions and methods for inhibiting expression

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 18 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8877917

Glycoconjugates of RNA interference agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8877726

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Nov 04 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 30 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8859750

RNAi modulation of RSV and therapeutic uses thereof

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8859516

Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Oct 14 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8828956

Carbohydrate conjugates as delivery agents for oligonucleotides

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Sep 09 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 04 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8809516

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8809292

Compositions and methods for inhibiting expression of the PCSK9 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 19 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8796436

Modified iRNA agents

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Aug 05 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 31 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8791250

Compositions and methods for inhibiting expression of the HAMP gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 29 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 24 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8765932

Compositions and methods for inhibiting expression of XBP-1 gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jul 01 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 26 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8754201

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 17 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 12 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8741866

Compositions and methods for inhibiting expression of transthyretin

Alnylam Pharmaceuticals, Inc. Β· Granted Tue Jun 03 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 29 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 8729037

Method and medicament for inhibiting the expression of a given gene

Alnylam Pharmaceuticals, Inc. Β· Granted Tue May 20 2014 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

granted